"10.1371_journal.pone.0033536","plos one","2012-03-28T00:00:00Z","Hanna Nohynek; Jukka Jokinen; Markku Partinen; Outi Vaarala; Turkka Kirjavainen; Jonas Sundman; Sari-Leena Himanen; Christer Hublin; Ilkka Julkunen; Päivi Olsén; Outi Saarenpää-Heikkilä; Terhi Kilpi","Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland; Helsinki Sleep Clinic, Vitalmed Research Centre, Helsinki, Finland; Department of Pediatrics, Childrens Hospital, Helsinki University Hospital, Helsinki, Finland; Department of Clinical Neurophysiology, Tampere University Hospital, Tampere, Finland; Finnish Institute of Occupational Health, Helsinki, Finland; Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland; Department of Child Neurology, Oulu University Hospital, Oulu, Finland; Department of Pediatrics, Tampere University Hospital, Tampere, Finland","Conceived and designed the experiments: JJ T. Kilpi HN. Analyzed the data: JJ T. Kilpi HN. Contributed reagents/materials/analysis tools: JJ JS. Wrote the paper: HN JJ MP OV T. Kirjavainen JS SLH CH IJ PO OSH T. Kilpi. Designed the database: JJ JS. Obtained permissions: JJ HN T. Kilpi. Obtained data: JJ JS HN. Validated cases: MP T. Kirjavainen PO SLH OSH CH.","HN received honoraria for technical consultancy from GlaxoSmithKline (GSK), and Pfizer for development of pneumococcal conjugate vaccines. JJ is co-investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline. MP has been consultant for Bioprojet and UCB Pharma and received funding support and travel grants from Boehringer-Ingelheim, Bioprojet, GSK, Cephalin, MSD, Leiras and Servier. T. Kilpi is principal investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline, and her unit received funding for a clinical trial on the safety and immunogenicity of a prototype pandemic influenza vaccine from Solvay Pharmaceuticals. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. All other authors confirm they have no conflicts of interest.","2012","03","Hanna Nohynek","HN",12,TRUE,2,NA,2,5,TRUE,FALSE,TRUE,5,"7;8;9;10;11",TRUE
